A phase II window trial of procarbazine and topotecan in children with high-grade glioma: A report from the children's oncology group

Journal of Neuro-Oncology

Volumn 77, Issue 2, 2006, Pages 193-198

  Chintagumpala, Murali M ^a   Friedman, Henry S ^b   Stewart, Clinton F ^c   Kepner, James ^d   McLendon, Roger E ^b   Modrich, Paul L ^b   McCluggage, Charles ^a   Burger, Peter ^e   Holmes, Emi ^d   Thompson, Stephen ^c   Rutka, James ^f   Michalski, Jeff ^g   Woo, Shiao ^a   Blaney, Susan M ^a   Kun, Larry E ^c   Horowitz, Marc E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AGT activity in high grade glioma in children; High grade glioma in children; Mismatch repair proteins in high grade glioma in children; Phase II window therapy in high grade glioma in children; Procarbazine in high grade glioma in children; Resistance mechanisms in high grade glioma in children; Topotecan in high grade glioma in children

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; DRUG METABOLITE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; PROCARBAZINE; PROTEIN MLH1; PROTEIN MSH2; TOPOTECAN; TOPOTECAN LACTONE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSFERASE;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE CALCULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM PERMISSIBLE DOSE; MINIMAL RESIDUAL DISEASE; MISMATCH REPAIR; NEUTROPHIL COUNT; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROTEIN DEFICIENCY; RADIOSURGERY; SKIN TOXICITY; STATISTICAL ANALYSIS; STEREOTAXIC SURGERY; TREATMENT REFUSAL; METABOLISM; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; SURVIVAL;

ADOLESCENT; ADULT; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTS HOMOLOG 2 PROTEIN; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROCARBAZINE; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 33747815410     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9024-x     Document Type: Article

References (28)

1. Cohen ME, Duffner PK, Tebbi CK: Brain tumors in children: Diagnosis and management. In: Cameron K. Tebbi (ed) Major Topics in Pediatric and Adolescent Oncology. G.K. Hall and Co., Boston, 1982
2. Sposto R, Ertel IJ, Jenkin RDT, et al The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial J Neuro Oncol 7: 165-177, 1989
3. Finlay JL, Boyett JM, Yates AL, et al Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen J Clin Oncol 13(1):112-123, 1995
4. Horowitz ME, Etcubanas E, Christensen ML, Houghton JA, George SL, Green AA, Houghton PJ: Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development J Clin Oncol 6(2):308-314, 1988
5. Smith MA, Anderson B, Phase II window studies: 10 years of experience and counting J Pediatric Hematol Oncol 23(6):334-337, 2001
6. Green SB, Byar DP, Walker MD, et al Comparisons of carmustine, procarbazine, and high-dose methylprednisone as additions to surgery and radiotherapy for the treatment of malignant glioma Cancer Treat Rpts 67(2): 121-132, 1983
7. Newton HB, Junck L, Bromberg J, et al Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure Neurology 40:1743-1746, 1990
8. Kumar ARV, Renaudin J, Wilson CB, et al Procarbazine hydrochloride in the treatment of brain tumors Neurosurgery 40:365-371, 1974
9. Newton HB, Bromberg J, Junck L, et al Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas J Neuro Oncol 15:257-263, 1993
10. Levin VA, Silver P, Hannigan J, et al Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report Int J Radiat Oncol 18(2):321-324, 1990
11. Friedman HS, Houghton PJ, Schold SC, et al Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Can Chem Phar 32(2):171-174, 1994
12. Blaney SM, Balis FM, Cole DE, et al Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion Can Res 53:1032-1036, 1993
13. Pratt CB, Stewart C, Santana VM, et al Phase I study of topotecan for pediatric patients with malignant solid tumors J Clin Oncol 12(3):539-543, 1994
14. Schold SC Jr, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, Swenberg JA, Kleihues P, O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts J Neurosurg 70(4):573-577, 1989
15. Friedman HS, Johnson SP, Dong Q, et al Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft Cancer Res 57(14):2933-2936, 1997
16. Friedman HS, McLendon RE, Kerby T et al.: DNA mismatch repair and O-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12): 3851-3857
17. Pratt CB, Stewart CF, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH, Phase I study of topotecan for pediatric patients with malignant solid tumors J Clin Oncol 12:539, 1994
18. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Xiaolong Luo, Poquette C, Houghton JA, Houghton PJ, Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts JNCI 90:505, 1998
19. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide, 1st edn. Biomedical Simulations Resource, USC, Los Angeles, 1990
20. Gibaldi M, Perrier D: Pharmacokinetics, 2nd edn. New York, 1982
21. 6-methylguanine-DNA methyltransferase in formalin-fixed paraffin-embedded astrocytomas Lab Invest 78:643-644, 1998
22. - cells Cancer Res 52:6404-6406, 1992
23. 6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts Carcinogenesis 17:219-224, 1996
24. Stewart: Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor (PNET) J Clin Oncol 22(16):3357-65, 2004
25. 6-methylguanine-DNA methyltransferase Carcinogenesis 15:577-582, 1994
26. Chang MN, Therneau TM, Wieand HS, Cha SS, Designs for group sequential phase II clinical trials Biometrics 43:865-875, 1987
27. Chang MN, O'Brien PC, Confidence intervals following group sequential tests Controlled Clin Trials 7:18-26, 1986
28. 6-Benzylguanine for patients undergoing surgery for malignant glioma J Clin Oncol 16:3570-3575, 1998